Exelixis | EXEL - 营业费用



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.83B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


营业费用 更改 日
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 10.04B 168M 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
Eisai JPY 209.6B 6.14B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 380.28M 20.8M 2026-06
Genmab DKK 748M 77M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sanofi EUR 8.98B 1.73B 2026-03
Takeda JPY 1.02T 89.68B 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Xencor USD 87.82M 5.44M 2026-06